Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva Seeks To Draw A Line Under Opioids Litigation With Final US Settlement

State Sign-On Process Still To Play Out As Teva ‘Optimistic’ Of High Participation Rate

Executive Summary

Teva has announced a finalized nationwide settlement over its long-running opioids litigation, signalling the start of a sign-on process for individual states, subdivisions and special districts. The company remains optimistic of a high participation rate.

You may also be interested in...



Teva Makes It Six With Kentucky Price-Fixing Settlement, As Trial Draws Nearer

Teva is continuing to knock down one-by-one US state price fixing-claims, with the prospect of a criminal trial beginning in May next year.

Five Big Legal Stories From 2022

Generics Bulletin looks back at a selection of the most significant legal stories from 2022, including a major victory in the UK on the Eliquis blood thinner giant and continued action on generic label carve outs, which has the potential to reverberate through the US industry.

Long-Awaited Nationwide Opioid Settlement To Move Forward For Teva

Teva has all but two US states on board for its long-hoped-for nationwide settlement to resolve opioid-related claims against the firm.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152318

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel